January 2024 in “Journal of Clinical Images and Medical Case Reports” Baricitinib may help treat frontal fibrosing alopecia and facial papules.
1 citations
,
May 2024 in “Dermatology and Therapy” Frontal Fibrosing Alopecia needs better diagnostics and treatments, with dutasteride showing promise.
1 citations
,
January 2018 in “Medical Science and Discovery” The document's conclusion cannot be provided as the content is not available for parsing.
5 citations
,
July 2019 in “Photodiagnosis and photodynamic therapy” Using tacalcitol ointment with photodynamic therapy may effectively treat follicular mucinosis with scalp hair loss.
September 2022 in “XXXIX Congresso Brasileiro de Reumatologia” Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
The man has Temporal Triangular Alopecia, a stable, non-scarring hair loss condition best treated with hair transplantation.
September 2025 in “Journal of the Pakistan Medical Association” Tofacitinib effectively and safely promotes hair regrowth in alopecia patients.
December 2016 in “Anales del sistema sanitario de Navarra” Frontal fibrosing alopecia is increasing, especially in postmenopausal women, and treatment with finasteride can improve it.
June 2020 in “Journal of Investigative Dermatology” Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.
16 citations
,
July 2017 in “Journal of American Association for Pediatric Ophthalmology and Strabismus” The modified Crawford technique resulted in less lagophthalmos and better cosmetic outcomes for patients with lateral droop.
8 citations
,
October 2016 in “Actas Dermo-Sifiliográficas” FFA in men, often mistaken for other hair loss types, may be more common than thought and needs larger studies for confirmation.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib may slow hair loss in scarring alopecias but is unlikely to regrow significant hair.
7 citations
,
August 1971 in “JAMA” Tinea faciale can be mistaken for lupus due to similar symptoms.
1 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.
7 citations
,
August 2019 in “American Journal of Dermatopathology” Frontal fibrosing alopecia on limbs shows permanent inflammatory hair loss, not typical scarring.
8 citations
,
July 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Certain microRNAs might help identify and understand Frontal Fibrosing Alopecia.
1 citations
,
December 2012 in “Journal of dermatological science” Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
222 citations
,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
1 citations
,
June 2022 in “International Journal of Infectious Diseases” A fungal infection was successfully treated with oral and topical antifungals after being misdiagnosed and worsened by corticosteroids.
April 2019 in “Journal of Investigative Dermatology” Targeting immune pathways like JAK/STAT may help treat frontal fibrosing alopecia.
March 2026 in “Journal of Investigative Dermatology” Folliculin slows hair growth, and blocking it might help treat hair loss.
47 citations
,
September 2012 in “Human molecular genetics online/Human molecular genetics” Folliculin deficiency causes problems with cell division and positioning due to disrupted RhoA signaling and interaction with p0071.
2 citations
,
July 2020 in “Giornale italiano di dermatologia e venereologia” A woman with frontal fibrosing alopecia experienced unusual hair growth after using a specific topical lotion.
10 citations
,
June 2022 in “Frontiers in Immunology” Fucoidan reduces bone cell formation by affecting T-cell activity.
1 citations
,
May 2025 in “Frontiers in Medicine” This retrospective case series evaluated the efficacy and safety of dual-targeted therapy (DTT) in 18 patients with refractory inflammatory bowel disease (IBD) across three tertiary hospitals in China. The study included 8 patients with ulcerative colitis and 10 with Crohn’s disease, using combinations of biologic agents and tofacitinib. Results showed high clinical response rates of 88.23% at 3 months, 91.67% at 6 months, and 100% at 9 months, with an endoscopic response in 88.89% of evaluated patients at 9 months. Adverse events were minimal, with some patients experiencing ustekinumab-associated arthralgia and alopecia, and tofacitinib-related allergic purpura, leading to a transition to monotherapy. Two patients developed infections but continued DTT after treatment. The study concludes that DTT is a promising and safe option for patients unresponsive to conventional monotherapies.
3 citations
,
May 1980 in “American Journal of Nursing” Scalp tourniquets did not significantly prevent hair loss from chemotherapy.
September 2017 in “Journal of Investigative Dermatology” Certain miRNAs might be involved in a hair loss condition called frontal fibrosing alopecia and could possibly help in its diagnosis.
May 2021 in “Experimental Cell Research” FOXC1 boosts SFRP1 in hair loss, suggesting new treatments.
8 citations
,
September 2016 in “Journal of Investigative Dermatology” Mice with more Flightless I protein grew back their claws better after amputation.
98 citations
,
January 2013 in “Journal of The American Academy of Dermatology” Dutasteride may help stabilize Frontal Fibrosing Alopecia, but more research is needed.